|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
single dose
|
|
gptkbp:alsoKnownAs
|
gptkb:sotrovimab
|
|
gptkbp:approvedBy
|
gptkb:Therapeutic_Goods_Administration
gptkb:UK_Medicines_and_Healthcare_products_Regulatory_Agency
gptkb:European_Medicines_Agency
2021
|
|
gptkbp:ATCCode
|
J06BD09
|
|
gptkbp:CASNumber
|
2471911-96-8
|
|
gptkbp:chemicalFormula
|
C6488H10008N1732O2026S46
|
|
gptkbp:developedBy
|
gptkb:Vir_Biotechnology
GlaxoSmithKline
|
|
gptkbp:drugClass
|
gptkb:monoclonal_antibody
|
|
gptkbp:indication
|
patients at risk of severe COVID-19
treatment of mild to moderate COVID-19
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
SARS-CoV-2 spike glycoprotein
|
|
gptkbp:mechanismOfAction
|
binds to SARS-CoV-2 spike protein
|
|
gptkbp:monitors
|
pharmacovigilance
|
|
gptkbp:notRecommendedFor
|
severe COVID-19 requiring oxygen
|
|
gptkbp:pregnancyCategory
|
gptkb:unknown
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
rash
hypersensitivity
infusion-related reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:UNII
|
6QY1D9K2F1
|
|
gptkbp:usedFor
|
gptkb:COVID-19
|
|
gptkbp:bfsParent
|
gptkb:Sotrovimab
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xevudy
|